Anticholinergic bladder drugs were associated with an increased risk of dementia compared with nonuse, but not when compared with the beta-3 agonist mirabegron.
The BrainSense Adaptive deep brain stimulation system is the first FDA-approved closed-loop neuromodulation therapy designed to automatically adjust stimulation in real time based on individual brain activity for patients with Parkinson’s disease.
Research shows that adults experiencing perceived taste loss face a higher risk of mortality, particularly when the ability to detect salt and sourness declines.